Table 1 Characteristics of HBsAg-positive individuals with or without hepatitis E
Characteristic | Total | Trial-participants | Non-trial-participants | ||||||
|---|---|---|---|---|---|---|---|---|---|
Test-positive cases (N = 96) | Test-negative controls (N = 2830) | P-value | Test-positive cases (N = 20) | Test-negative controls (N = 580) | P-value | Test-positive cases (N = 76) | Test-negative controls (N = 2250) | P-value | |
Age at the onset of symptom-Median (IQR), years | 53.5 (44.0–63.0) | 49.0 (40.0–58.0) | 0.0028 | 55.0 (44.0–59.0) | 51.5 (44.0–59.0) | 0.4379 | 52.0 (44.5, 63.0) | 48.0 (38.0, 57.0) | 0.0034 |
Sex—n (%) | |||||||||
Male | 61 (63.5) | 1637 (57.8) | 0.2660 | 15 (75.0) | 296 (51.0) | 0.0350 | 46 (60.5) | 1341 (59.6) | 0.8714 |
Female | 35 (36.5) | 1193 (42.2) | 5 (25.0) | 284 (49.0) | 30 (39.5) | 909 (40.4) | |||
Peak alanine aminotransferase—GM ± SD, ×ULN | 15.2 ± 3.1 | 5.6 ± 2.1 | <0.0001 | 25.1 ± 2.5 | 5.4 ± 2.2 | <0.0001 | 13.3 ± 3.1 | 5.6 ± 2.1 | <0.0001 |
HEV vaccination history—n (%) | |||||||||
No | 93 (96.9) | 2551 (90.1) | 0.0279 | 17 (85.0) | 301 (51.9) | 0.0035 | 76 (100.0) | 2250 (100.0) | NA |
Yes | 3 (3.1) | 279 (9.9) | 3 (15.0) | 279 (48.1) | 0 (0) | 0 (0) | |||
Interval between the onset of symptom and last dose—Median (IQR), months | 40.2 (21.3, 79.5) | 62.3 (40.0, 86.9) | 0.4379 | 40.2 (21.3, 79.5) | 62.3 (40.0, 86.9) | 0.4379 | - | - | - |
1-dose | 0 (0.0) | 20 (0.7) | 0.8298 | 0 (0.0) | 20 (3.4) | 0.8298 | - | - | - |
2-dose | 0 (0.0) | 11 (0.4) | 0 (0.0) | 11 (1.9) | - | - | |||
3-dose | 3 (3.1) | 248 (8.8) | 3 (15.0) | 248 (42.8) | - | - | |||
